Should You Buy Compass Therapeutics Inc. (CMPX) Today? Analysis, Price Targets, and 2026 Outlook.
No data
No data
Growth
Profitability
Efficiency
Wall Street analysts forecast CMPX stock price to rise
8 Analyst Rating
Wall Street analysts forecast CMPX stock price to rise
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.830
Low
8
Averages
12.67
High
24
Current: 1.830
Low
8
Averages
12.67
High
24
Raymond James
Sean McCutcheon
Outperform -> Market Perform
downgrade
$NULL
AI Analysis
2026-04-28
Reason
Raymond James
Sean McCutcheon
Price Target
$NULL
AI Analysis
2026-04-28
downgrade
Outperform -> Market Perform
Reason
Raymond James analyst Sean McCutcheon downgraded Compass Therapeutics to Market Perform from Outperform with no price target after Compass disclosed survival outcomes from COMPANION-002, the Phase 3 trial of tovecimig in combination with paclitaxel for the treatment of second line biliary tract cancer. The dataset \"sits within the true bear scenario from our preview of the readout,\" says the analyst, whose confidence in the approval and a potential commercialization of tovecimig in 2L BTC is reduced.
Canaccord
Buy
downgrade
$13 -> $7
2026-04-28
Reason
Canaccord
Price Target
$13 -> $7
2026-04-28
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Compass Therapeutics to $7 from $13 and keeps a Buy rating on the shares. The firm said Tovecimig+paclitaxel clearly improves progression-free survival vs paclitaxel monotherapy, but 54% crossover confounded any possible overall survival benefit in the ITT population. The active arm did however show numerically superior overall survival to patients that did not crossover, but they doubt the FDA would consider this to be sufficient for full approval.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CMPX
